Skip to main content
Contact Us
Subscribe
E-Edition
74°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Adlai Nortye Ltd.
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
April 10, 2025
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
August 08, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
August 08, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
May 23, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
May 22, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
March 29, 2024
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
November 17, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
October 23, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
October 03, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
September 29, 2023
From
Adlai Nortye Ltd.
Via
GlobeNewswire
Tickers
ANL
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.